A2780
Cat.No.: CSC-C9491J
Species: Homo sapiens (Human)
Source: Ovary
Morphology: Epithelial
Culture Properties: Adherent
- Specification
- Background
- Scientific Data
- Q & A
- Customer Review
Never can cryopreserved cells be kept at -20 °C.
A2780 is a human ovarian endometrioid adenocarcinoma cell line, originally established in 1972 from an untreated patient with advanced-stage disease. Its singular scientific advantage resides in its status as the chemotherapy-sensitive parental archetype for isogenic drug resistance research. Unlike heterogeneous patient samples, A2780 provides a pure, syngeneic background against which resistance mechanisms can be experimentally isolated.
The line's power lies in its derivative platform. Chronic exposure of A2780 to cisplatin and adriamycin has generated the widely adopted resistant sublines A2780cis and A2780ADR, which exhibit cross-resistance to melphalan, vinblastine, and irradiation. This matched pair enables precise dissection of ATP-binding cassette (ABC) transporter efflux (MDR1/BCRP), EMT programming (VIM, SNAIL1/2), and ECM-mediated chemoprotection-mechanisms often confounded in non-isogenic comparisons.
Genomically, A2780 harbors clinically relevant driver mutations in TP53, BRCA1, PTEN (homozygous deletion), PIK3CA, and ATM. It retains stable, authenticated STR profiles and forms tumors in nude mice, bridging monolayer screening and in vivo efficacy. Critically, A2780 is exquisitely amenable to 3D multicellular spheroid culture, a configuration that recapitulates solid tumor hypoxia, G0-G1 cell cycle arrest, and p27-mediated chemoresistance-features lost in 2D.
NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines
Background
This study compares NMR metabolomics profiles of A2780 ovarian cancer cells, cisplatin-resistant A2780cis, and primary high-grade serous ovarian cancer cells from 10 patients. Primary cells from solid tumors and ascites are metabolically similar to each other but differ significantly from A2780 and A2780cis. Exo-metabolome of patient-derived cells is closer to resistant A2780cis, while endo-metabolome is intermediate. Primary cells show pronounced glycolytic phenotype; A2780cis diverges via resistance markers like glutathione and taurine. Findings highlight limitations of A2780 as a representative HGSOC model and support A2780cis for resistance studies.
Key Findings
NMR metabolomics revealed that primary high-grade serous ovarian cancer (HGSOC) cells, whether derived from solid tumors (HGSOC_T) or ascites (HGSOC_A), share highly similar metabolic profiles across patients, but differ markedly from A2780 and cisplatin-resistant A2780cis cell lines. In the exo-metabolome, HGSOC_T cells cluster near A2780cis, while HGSOC_A cells separate; in the endo-metabolome, HGSOC cells are intermediate between A2780 and A2780cis. Primary cells display the most pronounced glycolytic phenotype, with increased glucose consumption, pyruvate uptake, and intracellular lactate. A2780cis cells are distinguished by elevated phosphocholine, glycerophosphocholine, glutathione, taurine, and altered urea cycle metabolites, indicating acquired cisplatin resistance mechanisms. HGSOC cells lack these resistance markers despite having higher cisplatin IC50 values than A2780. Additionally, UDP-sugar and nucleotide profiles differ: UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine are detectable only in immortalized lines, whereas UDP-glucose and inosine are specific to primary HGSOC cells. The study demonstrates that A2780 is not a faithful metabolic model of HGSOC, whereas A2780cis better mirrors some exo-metabolic features of primary cells.
Contribution
Creative Bioarray supplied the A2780 human ovarian carcinoma cell line and its cisplatin-resistant counterpart A2780cis (catalogue nos. CSC-C9491J and CSC-C9492J) used as established in vitro models. These cells enabled comparative NMR metabolomics against patient-derived HGSOC cells, serving as sensitive and resistant references throughout the study.
Fluorescent NHC Gold(I) Complexes as Tools for Target Identification and Metallomic Studies in Cancer Cells
Background
This study reports three fluorescent NHC gold(I) complexes designed as trackable metallodrug models. Two anthracenyl-labeled complexes (3, 4) and one BODIPY-labeled complex (5) were synthesized and characterized. Their interactions with human serum albumin were examined by UV–vis and ESI-MS, revealing compound-dependent binding. Cellular uptake was monitored by FACS in cisplatin-sensitive and resistant A2780 ovarian cancer cells, and subcellular distribution was quantified by fractionation. The anthracenyl complexes retained cytotoxicity, with biscarbene 4 being most active and preferentially accumulating in mitochondria, supporting fluorescent tagging for mechanistic and metallomic studies.
Key Findings
Three NHC gold(I) complexes bearing anthracenyl (3, 4) or BODIPY (5) fluorescent tags were prepared. Anthracenyl monocarbene 3 and biscarbene 4 remained cytotoxic in A2780 cells; cationic biscarbene 4 was more potent than 3 and, notably, both were more active against cisplatin-resistant A2780/R than sensitive A2780/S cells. Complex 5 was too insoluble for reliable IC50 determination and showed unsuitable broad fluorescence. HSA studies showed that 3 forms covalent Au-NHC adducts, 4 interacts weakly/noncovalently, and 5 undergoes ligand displacement with gold(I) binding to HSA. FACS revealed efficient uptake of 3 and 4, with higher signal for 4. Subcellular fractionation showed preferential mitochondrial accumulation of both anthracenyl complexes. These results provide proof-of-concept that fluorescently labeled gold(I) NHC complexes can track uptake, subcellular fate, and protein interactions for metallomic target identification.
Contribution
Creative Bioarray supplied the A2780 human ovarian cancer cell lines used in this study, including cisplatin-sensitive (Lot CSC-C9491J) and cisplatin-resistant (Lot CSC-C9492J) variants. These authenticated cells enabled the MTT cytotoxicity assays, flow-cytometry uptake measurements, and subcellular fractionation experiments, supporting evaluation of the fluorescent gold(I) NHC complexes.
Thiosugar-functionalized gold(I)-NHC complexes as selective anticancer agents for potential targeted therapy
Background
This study reports four novel gold(I)-NHC complexes, two conjugated to a thiosugar moiety, designed as selective anticancer agents against ovarian cancer. The complexes were characterized and assessed for human serum albumin binding, lipophilicity, cytotoxicity in A2780 sensitive/resistant and SKOV-3 cells, and healthy HSkMC cells, plus TrxR inhibition, confocal microscopy and FACS uptake. Thiosugar conjugation improved potency, selectivity and cellular uptake, while peptide bioconjugates mostly failed to improve activity except LHRH-like peptide conjugates, which showed slight gains.
Key Findings
Four Au(I)-NHC complexes (1a-b, 2a-b) were synthesized; 2a-b bear 3,4,5,6-tetra-O-acetyl-1-thio-β-D-glucopyranose and an anthracenyl fluorescent tag. Thiosugar conjugation markedly enhanced cytotoxicity in A2780/S, A2780/R and SKOV-3 ovarian cancer cells, with IC50 values around 4–6 µM for 2a-b, while retaining >100 µM IC50 in healthy HSkMC cells and improving selectivity indices (>18) beyond auranofin. Confocal microscopy and FACS showed increased cellular uptake for 2a-b versus 1a-b. All complexes inhibited thioredoxin reductase; 2a was most effective. ESI-MS revealed HSA adducts for all complexes, but fluorescence quenching indicated reversible HSA binding only for non-thiosugar complexes 1a-b. GLUT-1 inhibition suggested thiosugar-mediated uptake partly for 2b, not 2a. Six peptide bioconjugates were synthesized; RGD and mitochondria-penetrating peptide conjugates lost selectivity, whereas LHRH analogue conjugates 9a-b showed slight cytotoxicity/selectivity improvement. Overall, thiosugar-functionalized Au(I)-NHC complexes are promising selective anti-ovarian cancer agents.
Contribution
Creative Bioarray provided the A2780/S and A2780/R human ovarian cancer cell lines (cisplatin-sensitive and cisplatin-resistant; lots CSC-C9491J, CSC-C9492J). These authenticated cell lines enabled cytotoxicity, TrxR inhibition, confocal, FACS uptake, and GLUT-1 inhibition assays, supporting evaluation of anticancer potency, selectivity, platinum-resistance overcoming, and thiosugar-mediated targeting of the gold(I)-NHC complexes.
Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin
Background
This study prepares and characterizes a well-defined bioconjugate (HuHf@AF) between the gold drug auranofin and human heavy-chain ferritin/apoferritin, with ~14 gold atoms per nanocage. Site-directed mutagenesis, ESI-MS, and ICP-OES show gold binds exclusively to Cys90 and Cys102. HuHf@AF is highly cytotoxic against A2780 ovarian cancer cells, overcomes cisplatin resistance, and induces NMR metabolomic changes similar to free auranofin. It also metalates the thioredoxin reductase selenopeptide. The ferritin nanocage stabilizes and controls gold delivery, suggesting a promising anticancer agent.
Key Findings
A stable, reproducible auranofin–human H-ferritin bioconjugate (HuHf@AF) was prepared without cage disassembly, containing ~13.8 ± 3.8 gold atoms per nanocage. ESI-MS and ICP-OES, combined with site-directed mutagenesis, demonstrated that gold binds exclusively at solvent-exposed Cys90 and Cys102; C130A did not affect binding, whereas C90A/C102A abolished it. HuHf@AF was stable in glutathione and HSA competition assays. It showed potent cytotoxicity against A2780 ovarian cancer cells (IC50 0.26 µM) and was ~3-fold more active than free auranofin. HuHf@AF also overcame cisplatin resistance in A2780cis cells more efficiently than free auranofin. NMR metabolomics revealed metabolic alterations nearly identical to free auranofin, with marked glutathione increase. ESI-MS documented gold transfer to the TrxR C-terminal dodecapeptide. 19F NMR and pH 4.5 studies indicated efficient cellular uptake and acid-facilitated gold release.
Contribution
Creative Bioarray supplied the A2780 human ovarian cancer and A2780 cisplatin-resistant (A2780cis) cell lines used as in vitro models. These authenticated cells enabled cytotoxicity testing, cisplatin-resistance evaluation, and NMR metabolomic profiling, supporting the conclusion that HuHf@AF is a potent anticancer bioconjugate.
Zein-Sodium Caseinate-Diosmin Nanoparticles as A Promising Anti-Cancer Agent with Targeted Efficacy Against A2780 Cell Line
This research investigated the potential of zein-sodium caseinate-diosmin nanoparticles (ZCD-NPs) as an anti-cancer agent against the A2780 cell line. Dynamic light scattering (DLS) analysis showed that ZCD-NPs have an average size of 265.30 nm with a polydispersity index of 0.21, indicating good uniformity suitable for pharmaceutical applications. Cytotoxicity assays showed a dose-dependent effect of ZCD-NPs, with A2780 cells showing significant sensitivity compared to normal HDF cells, indicating selective targeting of cancer cells. Flow cytometry analysis confirmed that ZCD-NPs induced apoptosis and necrosis in A2780 cells, as evidenced by increased expression of apoptotic genes such as p53 and caspases 8 and 9. In addition, ZCD-NPs exhibited potent antioxidant activity, effectively scavenging free radicals. These results suggest that ZCD-NPs have promising properties for targeted cancer therapy and antioxidant applications, which warrant further exploration in clinical settings.


Ask a Question
Write your own review
- Adipose Tissue-Derived Stem Cells
- Human Neurons
- Mouse Probe
- Whole Chromosome Painting Probes
- Hepatic Cells
- Renal Cells
- In Vitro ADME Kits
- Tissue Microarray
- Tissue Blocks
- Tissue Sections
- FFPE Cell Pellet
- Probe
- Centromere Probes
- Telomere Probes
- Satellite Enumeration Probes
- Subtelomere Specific Probes
- Bacterial Probes
- ISH/FISH Probes
- Exosome Isolation Kit
- Human Adult Stem Cells
- Mouse Stem Cells
- iPSCs
- Mouse Embryonic Stem Cells
- iPSC Differentiation Kits
- Mesenchymal Stem Cells
- Immortalized Human Cells
- Immortalized Murine Cells
- Cell Immortalization Kit
- Adipose Cells
- Cardiac Cells
- Dermal Cells
- Epidermal Cells
- Peripheral Blood Mononuclear Cells
- Umbilical Cord Cells
- Monkey Primary Cells
- Mouse Primary Cells
- Breast Tumor Cells
- Colorectal Tumor Cells
- Esophageal Tumor Cells
- Lung Tumor Cells
- Leukemia/Lymphoma/Myeloma Cells
- Ovarian Tumor Cells
- Pancreatic Tumor Cells
- Mouse Tumor Cells